Código QR (código de barras bidimensional)

Case Report: CD19 and CD22 CAR-T therapy induced durable complete remission in a patient with refractory plasmablastic lymphoma

IntroductionPlasmablastic lymphoma (PBL) is a rare and highly aggressive form of non-Hodgkin lymphoma that is associated with a poor prognosis. Traditional chemotherapy has demonstrated limited efficacy for PBL. There is currently no standard treatment for patients with refractory or relapsing PBL....

ver descrição completa

Na minha lista:
Principais autores: Dan Liu, Haichen Wei, Yanran Hu, Hui Wang, Ping Li, Ke Lu, Wenjun Zhang, Lijie Xing, Zengjun Li
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2025-10-01
coleção:Frontiers in Immunology
Assuntos:
plasmablastic lymphoma
refractory
car-t
bortezomib
daratumumab
Acesso em linha:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1697566/full
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados